BC Cancer researchers are playing a central role in a new international collaboration aimed at developing innovative treatments for osteosarcoma — a highly malignant bone cancer that commonly affects children and adolescents.
This year, approximately 4,060 British Columbians will be diagnosed with breast cancer. While many forms of breast cancer can be treated successfully, triple negative breast cancer (TNBC) remains the most deadly subtype because it is resistant to most forms of treatment.
Scientists had previously noted that the presence of a large protein called MondoA was associated with worse outcomes in several pediatric cancers, but they didn’t understand why.
BC Cancer Foundation is the fundraising partner of BC Cancer, which includes BC Cancer Research. Together with our donors, we are changing cancer outcomes for British Columbians by funding innovative research and personalized treatment and care.